Government-Owned Inventions; Availability for Licensing, 11475 [2017-03452]

Download as PDF Federal Register / Vol. 82, No. 35 / Thursday, February 23, 2017 / Notices Place: National Institutes of Health, 6701 Rockledge Drive, Bethesda, MD 20892, (Telephone Conference Call). Contact Person: Syed M Quadri, Ph.D., Scientific Review Officer, Center for Scientific Review, National Institutes of Health, 6701 Rockledge Drive, Room 6210, MSC 7804, Bethesda, MD 20892, 301–435– 1211, quadris@csr.nih.gov. Name of Committee: Center for Scientific Review Special Emphasis Panel; Member Conflict: Emerging Technologies in Neuroscience. Date: March 24, 2017. Time: 10:00 a.m. to 4:00 p.m. Agenda: To review and evaluate grant applications. Place: National Institutes of Health, 6701 Rockledge Drive, Bethesda, MD 20892, (Virtual Meeting). Contact Person: Sharon S Low, Ph.D., Scientific Review Officer, Center for Scientific Review, National Institutes of Health, 6701 Rockledge Drive, Room 5104, MSC 5104, Bethesda, MD 20892–5104, 301– 237–1487, lowss@csr.nih.gov. (Catalogue of Federal Domestic Assistance Program Nos. 93.306, Comparative Medicine; 93.333, Clinical Research, 93.306, 93.333, 93.337, 93.393–93.396, 93.837–93.844, 93.846–93.878, 93.892, 93.893, National Institutes of Health, HHS) Dated: February 17, 2017. Anna Snouffer, Deputy Director, Office of Federal Advisory Committee Policy. [FR Doc. 2017–03528 Filed 2–22–17; 8:45 am] BILLING CODE 4140–01–P DEPARTMENT OF HEALTH AND HUMAN SERVICES National Institutes of Health Government-Owned Inventions; Availability for Licensing AGENCY: National Institutes of Health, HHS. ACTION: Notice. The invention listed below is owned by an agency of the U.S. Government and is available for licensing to achieve expeditious commercialization of results of federally-funded research and development. Foreign patent applications are filed on selected inventions to extend market coverage for companies and may also be available for licensing. FOR FURTHER INFORMATION CONTACT: Licensing information and copies of the patent applications listed below may be obtained by communicating with the indicated licensing contact at the Technology Transfer and Intellectual Property Office, National Institute of Allergy and Infectious Diseases, 5601 Fishers Lane, Rockville, MD, 20852; tel. rmajette on DSK2TPTVN1PROD with NOTICES SUMMARY: VerDate Sep<11>2014 14:10 Feb 22, 2017 Jkt 241001 301–496–2644. A signed Confidential Disclosure Agreement will be required to receive copies of unpublished patent applications. SUPPLEMENTARY INFORMATION: Technology description follows. CD300b Expression Exacerbates Endotoxemia and Septic Peritonitis Description of Technology: The innate immune system is the first line of host defense against invading pathogens. Lipopolysaccharides (LPS), present in gram-negative bacteria membranes, cause strong immune responses following detection by the Toll-like receptor 4 (TLR4) on immune cells. This detection results in the release of proinflammatory cytokines, such as tumor necrosis factor alpha, interleukin-6, and interferon gamma, to assist with clearance of the infectious insult. In parallel, interleukin-10 (IL–10), an antiinflammatory cytokine, is induced to limit the immune response. This is because unchecked immune activation leads to a more severe immunopathology, such as septic shock and subsequently death. Current therapies to treat sepsis are ineffective, and clinical trials based on neutralization of specific inflammatory cytokines have failed. The inventors, listed below, have discovered that CD300b is a LPS binding receptor. This interaction results in a reduced IL–10 production, leading to an amplification of lethal inflammation. In vitro, anti-CD300b antibodies block LPS binding to CD300b, stopping association with TLR4 and CD14 and increases IL–10 levels. In vivo, administration of antiCD300b antibodies protects animals from septic shock, due to a reduce level of pro-inflammatory cytokines but subsequent increase in the antiinflammatory cytokine, IL–10. This technology is available for licensing for commercial development in accordance with 35 U.S.C. 209 and 37 CFR part 404, as well as for further development and evaluation under a research collaboration. Potential Commercial Applications: As a means of treating endotoxemia and septic peritonitis. Competitive Advantages: No current therapeutics are available to treat septic shock. Development Stage: Pre-clinical. Inventors: John E. Coligan, NIAID, NIH Oliver H. Voss, NIAID, NIH Konrad Krzewski, NIAID, NIH Publications: Voss, Oliver H., et al. ‘‘Lipopolysaccharide-induced CD300b receptor binding to toll-like receptor 4 PO 00000 Frm 00050 Fmt 4703 Sfmt 4703 11475 alters signaling to drive cytokine responses that enhance septic shock.’’ Immunity 44.6 (2016): 1365–1378. Intellectual Property: HHS Reference No. E–112–2016/0—U.S. Patent Application No. 62/308,144 filed 03/14/ 2016. Licensing Contact: Chris Kornak, 240– 627–3705, chris.kornak@nih.gov. Collaborative Research Opportunity: The National Institute of Allergy and Infectious Diseases is seeking statements of capability or interest from parties interested in collaborative research to further co-develop CD300b antagonists. For collaboration opportunities, please contact Chris Kornak, 240–627–3705, chris.kornak@nih.gov. Dated: February 16, 2017. Suzanne Frisbie, Deputy Director, Technology Transfer and Intellectual Property Office, National Institute of Allergy and Infectious Diseases. [FR Doc. 2017–03452 Filed 2–22–17; 8:45 am] BILLING CODE 4140–01–P DEPARTMENT OF HEALTH AND HUMAN SERVICES National Institutes of Health National Institute of Allergy and Infectious Diseases; Notice of Closed Meeting Pursuant to section 10(d) of the Federal Advisory Committee Act, as amended (5 U.S.C. App.), notice is hereby given of the following meeting. The meeting will be closed to the public in accordance with the provisions set forth in sections 552b(c)(4) and 552b(c)(6), Title 5 U.S.C., as amended. The grant applications and the discussions could disclose confidential trade secrets or commercial property such as patentable material, and personal information concerning individuals associated with the grant applications, the disclosure of which would constitute a clearly unwarranted invasion of personal privacy. Name of Committee: National Institute of Allergy and Infectious Diseases Special Emphasis Panel, Elucidation of Mechanisms of Radiation-Induced Endovascular Injury and Development of Treatments/Mitigators for Radiation-Induced Endothelial Cell and Vascular Dysfunction (U01). Date: March 16–17, 2017. Time: 10:00 a.m. to 5:00 p.m. Agenda: To review and evaluate grant applications. Place: National Institutes of Health, 5601 Fishers Lane, Rockville, MD 20892, (Telephone Conference Call). Contact Person: Zhuqing (Charlie) Li, Ph.D., Scientific Review Officer, Scientific Review Program, Division of Extramural E:\FR\FM\23FEN1.SGM 23FEN1

Agencies

[Federal Register Volume 82, Number 35 (Thursday, February 23, 2017)]
[Notices]
[Page 11475]
From the Federal Register Online via the Government Publishing Office [www.gpo.gov]
[FR Doc No: 2017-03452]


-----------------------------------------------------------------------

DEPARTMENT OF HEALTH AND HUMAN SERVICES

National Institutes of Health


Government-Owned Inventions; Availability for Licensing

AGENCY: National Institutes of Health, HHS.

ACTION: Notice.

-----------------------------------------------------------------------

SUMMARY: The invention listed below is owned by an agency of the U.S. 
Government and is available for licensing to achieve expeditious 
commercialization of results of federally-funded research and 
development. Foreign patent applications are filed on selected 
inventions to extend market coverage for companies and may also be 
available for licensing.

FOR FURTHER INFORMATION CONTACT: Licensing information and copies of 
the patent applications listed below may be obtained by communicating 
with the indicated licensing contact at the Technology Transfer and 
Intellectual Property Office, National Institute of Allergy and 
Infectious Diseases, 5601 Fishers Lane, Rockville, MD, 20852; tel. 301-
496-2644. A signed Confidential Disclosure Agreement will be required 
to receive copies of unpublished patent applications.

SUPPLEMENTARY INFORMATION: Technology description follows.

CD300b Expression Exacerbates Endotoxemia and Septic Peritonitis

    Description of Technology: The innate immune system is the first 
line of host defense against invading pathogens. Lipopolysaccharides 
(LPS), present in gram-negative bacteria membranes, cause strong immune 
responses following detection by the Toll-like receptor 4 (TLR4) on 
immune cells. This detection results in the release of pro-inflammatory 
cytokines, such as tumor necrosis factor alpha, interleukin-6, and 
interferon gamma, to assist with clearance of the infectious insult. In 
parallel, interleukin-10 (IL-10), an anti-inflammatory cytokine, is 
induced to limit the immune response. This is because unchecked immune 
activation leads to a more severe immunopathology, such as septic shock 
and subsequently death. Current therapies to treat sepsis are 
ineffective, and clinical trials based on neutralization of specific 
inflammatory cytokines have failed.
    The inventors, listed below, have discovered that CD300b is a LPS 
binding receptor. This interaction results in a reduced IL-10 
production, leading to an amplification of lethal inflammation. In 
vitro, anti-CD300b antibodies block LPS binding to CD300b, stopping 
association with TLR4 and CD14 and increases IL-10 levels. In vivo, 
administration of anti-CD300b antibodies protects animals from septic 
shock, due to a reduce level of pro-inflammatory cytokines but 
subsequent increase in the anti-inflammatory cytokine, IL-10.
    This technology is available for licensing for commercial 
development in accordance with 35 U.S.C. 209 and 37 CFR part 404, as 
well as for further development and evaluation under a research 
collaboration.
    Potential Commercial Applications: As a means of treating 
endotoxemia and septic peritonitis.
    Competitive Advantages: No current therapeutics are available to 
treat septic shock.
    Development Stage: Pre-clinical.

    Inventors:

John E. Coligan, NIAID, NIH
Oliver H. Voss, NIAID, NIH
Konrad Krzewski, NIAID, NIH

    Publications: Voss, Oliver H., et al. ``Lipopolysaccharide-induced 
CD300b receptor binding to toll-like receptor 4 alters signaling to 
drive cytokine responses that enhance septic shock.'' Immunity 44.6 
(2016): 1365-1378.
    Intellectual Property: HHS Reference No. E-112-2016/0--U.S. Patent 
Application No. 62/308,144 filed 03/14/2016.
    Licensing Contact: Chris Kornak, 240-627-3705, 
chris.kornak@nih.gov.
    Collaborative Research Opportunity: The National Institute of 
Allergy and Infectious Diseases is seeking statements of capability or 
interest from parties interested in collaborative research to further 
co-develop CD300b antagonists. For collaboration opportunities, please 
contact Chris Kornak, 240-627-3705, chris.kornak@nih.gov.

    Dated: February 16, 2017.
Suzanne Frisbie,
Deputy Director, Technology Transfer and Intellectual Property Office, 
National Institute of Allergy and Infectious Diseases.
[FR Doc. 2017-03452 Filed 2-22-17; 8:45 am]
 BILLING CODE 4140-01-P

This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.